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Cognitive Behavioral Therapy (CBT)Major depressive disorder (MDD) is a debilitating disorder and its pathophysiology is associated with deregula-
tion of the immune system. We investigated the changes in circulating levels of proinﬂammatory cytokines
(speciﬁcally IL-6 and TNF-α) measured by the ELISA kit in two psychotherapeutic interventions for MDD:
Narrative Cognitive Therapy (NCT) and Cognitive Behavioral Therapy (CBT). This is a randomized clinical trial
including 97 individuals (18 to 29 years-old) with MDD. In CBT there was a signiﬁcant difference in serum levels
of IL-6 and TNF-α, therefore indicating that CBT was more effective than NCT on serum levels proinﬂammatory
cytokines.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Major depressive disorder (MDD) is a debilitating disorder with a
lifetime prevalence ranging from 10% to 15% (Luca et al., 2013). The
pathogenesis of this disorder is not completely understood, however
studies have suggested that deregulation of the immune system,
particularly the inﬂammatory cytokines, is associated with the physio-
pathology of depression (Blume et al., 2011; Dowlati et al., 2010).
Cytokines are polypeptides with immunoregulating andmodulating
functions of the neural system (Wang et al., 2002). Proinﬂammatory
cytokines, such as the Interleukin-6 (IL-6) and the Tumor Necrosis
Factor alpha (TNF-α), play important roles in the central nervous
system, including synaptogenesis and neuronal plasticity (Kim et al.,
2013;Maes et al., 2012). Studies have suggested that depressed patients
show increased levels of proinﬂammatory cytokines (Munzer et al.,
2013; Schiepers et al., 2005). Furthermore, this increase seems to be
correlated to the severity of this psychiatric disorder (Maes et al.,
2012; Schiepers et al., 2005).
Pharmacological treatments act onmodulating cytokine production,
decreasing its levels (Hannestad et al., 2011; Munzer et al., 2013).
However, little is known about the effect of psychotherapy in reducing
these levels. Cognitive Behavioral Therapy (CBT) has been effectiveom.2015.06.003.
cias Clínicas Programa de Pós-
iências da Vida e da Saúde,
73 Sala 324 Prédio C, Centro-
er).in improving depressive symptoms (Butler et al., 2006), but few
studies have showed changes in inﬂammatory parameters after non-
pharmacological interventions (e.g., hypnosis, relaxation, mindfulness-
based and cognitive-behavioral training) (Keri et al., 2014). The aim of
this study was to determine whether psychotherapeutic interventions
for MDD are associated with changes in circulating levels of inﬂamma-
tory cytokines, speciﬁcally IL-6 and TNF-α.2. Methods
2.1. Design
This is a randomized clinical trial that assesses the effectiveness of
brief psychotherapy models in the regulation of pro-inﬂammatory
markers in remission of the depressive symptoms. A convenience
sample was recruited through advertisements at Community Health
Centers and local media.2.2. Participants
Evaluations were conducted at baseline and post-intervention.
Inclusion criteria for participating in the study were: (a) age range of
18–29 years, and (b) depression disorder diagnosed according to the
Structured Clinical Interview for DSM-IV (SCID). SCID translation and
adaptation to Portuguese showed good reliability, with Kappa
coefﬁcient of 0.87 for mood disorders (Del-Ben et al., 1996). Exclusion
criteria were: (a) current psychological or psychiatric treatment;
(b) currentmoderate/severe suicide risk; (c) current use of psychoactive
substances (except for tobacco and alcohol); and (d) bipolar depression.
Table 1
Baseline demographic and clinical characteristics of each group.
Characteristics NCT CBT p value
Gendera 0.521
Female 31 (81.6%) 21 (75%)
Male 7 (18.4%) 7 (25%)
Age (years)b 23.89 ± 3.18 24.46 ± 3.61 0.508
Scholarity (years)b 12.71 ± 3.05 12.59 ± 2.91 0.883
Brazilian Economic indexa 0.801
1 (Minor) 12 (31.6%) 9 (33.3%)
2 (Middle) 12 (31.6%) 9 (33.3%)
3 (Highest) 14 (36.8%) 9 (33.3%)
HDRSb 38 (12.4%) 28 (11.6%) 0.322
Legend: NCT = Narrative Cognitive Therapy; CBT = Cognitive Behavioral Therapy;
HDRS = Hamilton Depressive Rating Scale.
a Analysis by χ2 test.
b Analysis by -t test.
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all ethical procedures established by the National Health Council, Reso-
lution number 196, October of 1996, were followed. The project was
approved by the ethical committee of the university, protocol number
2009/24.
2.3. Interventions
The handbook of Cognitive Behavioral Therapy (CBT)was structured
in agreement with Aaron Beck's theory (Beck, 1997). This model of
psychotherapy proposes that the distorted or dysfunctional thinking
which inﬂuences mood and behavior is common to all psychological
disorders. An accurate assessment and modiﬁcation in thinking lead to
improvements in mood and behavior. Lasting improvements result
from the modiﬁcation of the basic dysfunctional beliefs.
The Handbook of Narrative Cognitive Therapy (NCT) was
established according to the proposition of Oscar Gonçalves (1998),
from the University of Minho (Portugal) (Gonçalves, 1998). This
model aims to reframe personal narratives by elaborating a new biogra-
phy based on life stories that lost meaning and became incoherent. The
new narratives and interpretations are integrated into the personal
stories in a coherent and meaningful way.
Both interventions were performed for seven weekly sessions
(one session a week) with one hour of duration, at the Hospital
Universitário São Francisco de Paula (HUSFP). The sessions were
conducted by undergraduate students in the last year of Psychology
from theUniversidade Católica de Pelotas (UCPel). All students received
two months of training and were weekly supervised by senior
psychologists.
2.4. Data collection
Participants were evaluated regarding sociodemographic data
(gender, age, and years of education). Economic status was measured
using the National Economic Index (NEI), an instrument that was
developed using as main component the analysis that considered the
Brazilian census of 2000 as a parameter. The instrument is based on
the individual's material assets and the education level of the head of
the household (Barros and Victora, 2005).
2.5. Outcome measures
TheHamiltonDepressionRating Scale (HDRS) (Hamilton, 1967)was
used to measure the severity of depressive symptoms at baseline and
post-intervention.
2.6. Biochemical analyses
For the biochemical analyses, 10 mL of blood were withdrawn from
each subject by venipuncture into an anticoagulant-free vacuum tube at
baseline and post-intervention. All venous blood samples were taken in
themorning (between 9:00 and 11:00 am). The bloodwas immediately
centrifuged at 4000 ×g for 10 min, and serum was kept frozen at
−80 °C until analysis. Serum IL-6 and TNF-α levels were measured
using a commercial immunoassay kit (DuoSet ELISA Development,
R&D Systems, Inc., USA). Serum IL-6 and TNF-α levels were expressed
in pg/mL.
2.7. Randomization
The randomization was performed by a person who was not
involved in the evaluation process or the therapeutic intervention;
this same person rafﬂed papers from a brown envelopewith the indica-
tion of the therapymodel. Subjects whomet the inclusion criteria wererandomized between the two models of brief interventions: NCT and
CBT.
2.8. Blinding
The researchers who were responsible for baseline and post-
intervention assessments and the participants were blinded regarding
the intervention model.
2.9. Statistical analysis
Statistical analysis was conducted in the SPSS 21.0 software. Chi-
square and t tests were used to assess data homogeneity between the
intervention models at baseline. Serum IL-6 and TNF-α levels had
non-Gaussian distributions. For nonparametric data, we usedWilcoxon
test. Serum cytokines levels were presented using median and inter-
quartile range. Results with p value ≤ 0.05 were considered statistically
signiﬁcant.
3. Results
We initially assessed 282 subjects. From these, a total of 162 subjects
did not meet the inclusion criteria, which resulted in 120 participants
(60NCT and 60CBT); 23 subjects (NCT=9andCBT=14)were exclud-
ed from our sample after scheduling the ﬁrst session and not attending
it for three times. We analyzed data from 97 participants (51 NCT and
46 CBT) at baseline.
During the intervention period, 23 participants (NCT = 12 and
CBT = 11) dropped out from the treatment reporting lack of time as
the main reason. The participants who presented suicide risk through-
out the intervention (NCT = 1 and CBT = 5) were excluded from
the study. They received psychological treatment and medication,
and their family was informed about the suicide risk. Therefore, 68
participants (NCT = 38 and CBT = 30) completed the therapy and
participated in the ﬁnal assessment. Nevertheless, two blood samples
from the CBT model could not be included in the analysis due to
hemolyzation.
There was no signiﬁcant difference between sociodemographic
variables and the therapy models. The average age was 23.89 ± 3.18
and 24.46 ± 3.61 in NCT and CBT, respectively. Also, 81.6% of the NCT
participants and 75% of the CBT participants are female. Moreover,
there was no difference in the severity of depressive symptoms
between therapy models (Table 1).
Severity of depressive symptoms was signiﬁcantly different from
baseline to post-intervention (p b 0.001) in NCT, whereas there was
no signiﬁcant difference in the serum levels of IL-6 (p = 0.987) and
TNF-α (p = 0.651) in this same intervention (Table 1). Regarding
the CBT intervention, there was a signiﬁcant difference on the severity
of depressive symptoms (p b 0.001), as well as in the serum levels of
Table 2
Median and interquartile interval of severity of depressive symptoms and serum IL-6 and TNF-α levels at baseline and post-intervention.
NCT CBT
Baseline Post-intervention p-Value⁎ Baseline Post-intervention p-Value⁎
HDRS 12.00 (10.00–14.25) 6.50 (3.75–10.00) b0.001 12.00 (8.25–14.00) 4.00 (1.25–6.00) b0.001
IL-6 (pg/mL) 12.90 (8.57–26.02) 14.08 (5.03–16.87) 0.987 17.82 (7.21–45.71) 10.19 (6.10–22.71) 0.042
TNF-α (pg/mL) 33.33 (21.29–65.86) 36.43 (24.58–3.83) 0.651 45.81 (31.83–89.14) 36.26 (26.86–64.00) 0.050
Legend: HDRS = Hamilton Depression Rating Scale; IL-6 = interleukin-6; TNF-α= tumor necrosis factor.
⁎ Analysis by Wilcoxon.
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CBT wasmore effective than NCT regarding the remission of depressive
symptoms (p = 0.018). There was no signiﬁcant correlation between
the remission of depressive symptoms and the changes in the serum
levels of IL-6 (r = 0.018; p = 0.933) and TNF-α (r = 0.067; p =
0.734) in the CBT, nor in the serum levels of IL-6 (r = 0.071; p =
0.679) and TNF-α (r =−0.026; p = 0.882) in the NCT.
4. Discussion
This randomized clinical trial evaluated the impact of two brief
cognitive therapy models for depression, CBT and NCT, on the serum
levels of proinﬂammatory cytokines (IL-6 and TNF-α). Depressive
symptoms were signiﬁcantly reduced at post-intervention on both
intervention models, and the CBT was more effective than NCT regard-
ing the remission of these symptoms. Therefore, the serum levels of
IL-6 and TNF-α signiﬁcantly decreased only in the patients treated
with CBT.
Depression has been associated with increased proinﬂammatory
cytokines levels, including IL-6 and TNF-α, which indicates a role of
inﬂammatory processes on the physiopathology of depression (Maes
et al., 2012; Miller et al., 2009; Schiepers et al., 2005). One metanalysis
of Dowlati et al. (2010) demonstrated that the only proinﬂammatory
markers that are signiﬁcantly increased in depressed patients are theFig. 1.Cytokines serum levels before and after treatmentwithNarrative Cognitive Therapy (NCT
CBT (p= 0.042); B) Serum IL-6 levels was not different after NCT (p= 0.987); C) Serum TNF-α
ferent after NCT (p = 0.651).IL-6 and TNF-α, as compared to healthy controls. Even though the aim
of this study was not to compare depressed patients with a control
group, we have identiﬁed increased serum levels of IL-6 and TNF-α at
baseline as compared to post-intervention. This corroborates the
existing relationship between depression and cytokines (Dantzer
et al., 2008; Haddad et al., 2002; Tian et al., 2014), in which the
increase of these cytokines may be related to a hyperactivity of the
hypothalamus-pituitary-adrenal (HPA) axis, which is the main
component of the endocrinal system of stress response and an impor-
tant well-known ethiological factor of depression. A recent metanalysis
showed that psychological stress was associated with an acute inﬂam-
matory response, with an increase in the levels of IL-6, IL-1β, TNF-α
and C-reactive protein (CPR) (Steptoe et al., 2007). The activation of
the HPA axis, with resulting increase in the levels of cortisol, and its
association with depression has been documented in several studies
(Burke et al., 2005; Cubala and Landowski, 2014; Matsuzaka et al.,
2013).
There is evidence that medication treatment has speciﬁc effects on
inﬂammatory response, and it is able to decrease the IL-6 levels in
depressed patients (Kubera et al., 2000; Maes et al., 2012; Schiepers
et al., 2005). One metanalysis of clinical trials veriﬁed the impact of
antidepressant medication on three inﬂammatory markers (IL-6, CPR
and IL-10), and observed a signiﬁcant decrease in the IL-6 and CPR levels
after treatment, whereas there was no signiﬁcant decrease in the IL-10) andCognitive Behavioral Therapy (CBT). A) Serum IL-6 levels decreased signiﬁcantly after
levels decreased signiﬁcantly after CBT (p = 0.050); D) Serum TNF-α levels was not dif-
146 F.P. Moreira et al. / Journal of Neuroimmunology 285 (2015) 143–146levels (Hannestad et al., 2011). In the sameway, Lanquillon et al. (2000)
observed a decrease in the TNF-α levels after pharmacological
treatment.
Studies that evaluate the impact of psychotherapeutic interventions
on depressive symptoms and on inﬂammatory markers are very
important, since they may play a fundamental role both on the preven-
tion of relapses and on the stability of the inﬂammatory markers. It is
important to highlight that the increase of inﬂammatory markers may
inﬂuence neural plasticity and result in new episodes of depression
throughout time (Khairova et al., 2009). Thus, psychotherapy models
that act on the remission of symptoms and neurobiological systems
changes, may be effective regarding the maintenance of symptom
remission and the prevention of new depressive episodes at long-term.
Some studies have demonstrated that CBT may be as effective as
psychopharmacological intervention for mood disorders, particularly
in the treatment of depression (DeRubeis et al., 2005). Hollon et al.
(2005) compared the effectiveness of CBT and antidepressive medica-
tion in depressed patients for 16 weeks, and they observed that the
patients who had been treated with CBT were less prone to relapses,
when compared to the other patients. One study that compared the
NCT and the CBT in the treatment of moderate depression veriﬁed
that the CBT was more effective than NCT in the improvement of
depressive symptoms (Lopes et al., 2014). The present study also
revealed a superiority of CBT in relation to NCT concerning the remis-
sion of depressive symptoms. This may be the main reason why we
veriﬁed a signiﬁcant decrease in the serum levels of IL-6 and TNF-α
only in CBT. One study with individuals presenting insomnia without
psychiatric disorders observed a decrease in the inﬂammatory cytokine
levels after CBT, although this decrease was not signiﬁcant (Chen et al.,
2008). The present study is among the ﬁrst ones to evaluate proinﬂam-
matory cytokine levels after brief cognitive therapy, which demon-
strates that CBT is effective in the treatment of depressive symptoms,
and it also decreases the concentrations of TNF-α and IL-6 in a sample
of young adults.
This study veriﬁed the effectiveness of a brief intervention in a
population of young adults, who are possibly in the ﬁrst mood episode
or have had a low number of recurrences. The results indicated an
improvement of the depressive symptoms and a decrease in the
proinﬂammatory cytokines serum levels at post-intervention. There-
fore, these ﬁndings are limited regarding their generalization to other
populations. Studies with other populations that evaluate the long-
term results of psychotherapy on cytokine serum levels, are important
to verify the maintenance of symptom improvement and prevention
of relapses.
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